semaglutide cardiac protection FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular US study confirms cardiovascular benefits

In a small 2023 study on the effect of semaglutide on obese PCOS patients who did not see improvement with lifestyle changes alone, 80% of participants lost at least 5% of their body weight over three months [3]

Reduced Muscle Mass Muscles generate heat

Who it fits: Patients who need cognitive performance support during a physical recovery cycle, or who want to address both systems simultaneously

To make that happen, well review your medical history and lifestyle to fashion a semaglutide plan that will get the results you desire

While it may be feasible to incorporate SLCO1B1 pharmacogenetic testing clinically, further well-designed randomized controlled trials are necessary to investigate its clinical utility